Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 16/20 | 0.33 |
| ▸ | NOTCH3 | Q9UM47 | 13/20 | 0.33 |
| ▸ | RBPJ | Q06330 | 3/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22660114 | 0.93 | NOTCH1 (0.34) | NOTCH1NOTCH3RBPJNOS2PSEN1 | |
| SCHEMBL29640533 | 0.84 | NOTCH1 (0.34) | NOTCH1NOTCH3RBPJ | |
| SCHEMBL5405574 | 0.79 | CA1 (0.31) | NOS2CA1CA2PSEN1PSEN2 | |
| SCHEMBL4057289 | 0.73 | NOS2 (0.32) | NOS2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24108958 | 0.71 | NOS2 (0.42) | NOS2 | |
| SCHEMBL1642298 | 0.71 | NOS2 (0.42) | NOS2 | |
| SCHEMBL1876375 | 0.71 | NOS2 (0.42) | NOS2 | |
| SCHEMBL9562376 | 0.71 | CA2 (0.52) | CA1CA2 | |
| SCHEMBL25958554 | 0.71 | CA1 (0.42) | NOS2CA1CA2 | |
| SCHEMBL377071 | 0.70 | FAAH (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3969001-A1 | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING NOTCH-ACTIVATED BREAST CANCER | Ayala Pharmaceuticals Inc. (US) | 2022-03-23 | — | — | EP | disclosed |